Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MoonLake ImmunotherapeuticsMLTX · Entity 4785 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MoonLake Immunotherapeutics
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to BuySEC Table II · derivative / convertible security · Conversion / exercise price $48.83 · Expires 2035-06-05 | Direct | 6,682 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 6,682 · Balance 6,682 F1: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 9, 2025 09:08 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 6,682 | $0.00 Strike: $48.83 | $0.00 |
DisclosureSEC source: 0001213900-25-052370 · ownership.xml · derivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,682 Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 171,000 | $53.72 | $9,186,120.00 |
DisclosureSEC source: 0001213900-24-086271 · ownership.xml · nonDerivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,980 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $53.00 to $55.34. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 16:59 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 7,688 | $0.00 Strike: $42.44 | $0.00 |
DisclosureSEC source: 0001213900-24-050826 · ownership.xml · derivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,688 Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 19:34 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionCommon shares, par value CHF 0.10 per share, of MoonLake AG · Derivative | 10,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001303 · ownership.xml · derivative · entry 3 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares, par value $0.0001 per share · 342,980 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 19:34 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Disposition to issuerClass C ordinary shares, par value $0.0001 per share | 342,980 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001303 · ownership.xml · nonDerivative · entry 2 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 19:34 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionClass A ordinary shares, par value $0.0001 per share | 342,980 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001303 · ownership.xml · nonDerivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:57 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 11,297 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001213900-23-048209 · ownership.xml · derivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,297 Underlying: Class A ordinary shares, par value $0.0001 per share · 11,297 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 8, 2024 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 06, 2022 Filed May 5, 2022 17:51 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 45,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001213900-22-024307 · ownership.xml · derivative · entry 1 Sturge Simon · CIK 0001920785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A ordinary shares, par value $0.0001 per share · 45,000 shares Expires 2032-04-06 F1 · derivative.exercise_date: Mr. Sturge was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.